Bucindolol: A pharmacogenomic perspective on its use in chronic heart failure

Clinical Medicine Insights: Cardiology

Volumn 5, Issue , 2011, Pages 55-66

  Smart, Neil A ^a   Kwok, Nigel ^a   Holland, David J ^a   Jayasighe, Rohan ^b   Giallauria, Francesco ^c  

^a UNIVERSITY OF NEW ENGLAND   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Beta blocker; Bucindolol; Chronic heart failure; Therapy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO;

ADRENERGIC ACTIVITY; AFRICAN AMERICAN; ANGINA PECTORIS; BRADYCARDIA; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG USE; GENE CONTROL; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART PALPITATION; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; INSOMNIA; INTERMITTENT CLAUDICATION; MORTALITY; PHARMACOGENOMICS; REVIEW; TACHYCARDIA;

EID: 84860398529     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S4309     Document Type: Review

References (80)

1. Cleland JG, McGowan J, Cowburn PJ. Beta-blockers for chronic heart failure: from prejudice to enlightenment. J Cardiovasc Pharmacol. 1998; 32 Suppl 1:S52-S60.
2. Cruickshank JM. Are we misunderstanding beta-blockers. International Journal of Cardiology. 9 Aug 2007;120(1):10-27.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 2 Jan 1999;353(9146):9-13.
4. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1 Nov 1995;26(5):1257-63.
5. Anderson JL, Krause-Steinrauf H, Goldman S, Clemson BS, Domanski MJ, Hager WD, et al. Failure of benefit and early hazard of bucindolol for Class IV heart failure. Journal of Cardiac Failure. Aug 2003;9(4):266-277.
6. Yancy CW. The role of race in heart failure therapy. Current Cardiology Reports. May 2002;4(3):218-215.
7. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 8 Feb 2000;101(5):558-569.
8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA, 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 14 Apr 2009;53(15):e1-e90.
9. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 4 Dec 1997;80(11A):26L-40L.
10. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. The American Journal of Medicine. Mar 1990;88(3):223-229.
11. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. Journal of Cardiovascular Pharmacology. Jun 1990;15(6):959-967.
12. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, et al. Bucin-dolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 21 May 2002;105(20):2429-2434.
13. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfeld BA, Deitchman D, Brown M, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. Aug 1990;82(2):473-483.
14. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. The American Journal of Cardiology. 1 Sep 1990;66(5):603-607.
15. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. Dec 1991;84(6):2426-2441.
16. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, et al. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology. May 1991;17(6):1373-1381.
17. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. Sep 1991;84(3):1024-1039.
18. Eichhorn EJ, Willard JE, Alvarez L, Kim AS, Glamann DB, Risser RC, et al. Are contraction and relaxation coupled in patients with and without congestive heart failure? Circulation. Jun 1992;85(6):2132-2139.
19. Bett N, Dryburgh L, Boyle C, Hawley C. Hemodynamic properties of bucindolol, a beta-adrenoreceptor blocking drug with vasodilator activity. The American Journal of Cardiology. 1 Mar 1986;57(8):678-681.
20. Ruffn RE, Crockett AJ, Alpers JH. The effect of bucindolol on the airway function of asthmatics. European Journal of Clinical Pharmacology. 1986;30(5):559-565.
21. Bristow M, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Deitchman, D. Dose response of beta blocker therapy in heart failure: a multicentre, randomized trial of bucindolol versus placebo. Circulation. 1990;82(4):111-674.
22. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. Apr 1994;89(4):1632-42.
23. Heesch CM, Marcoux L, Hatfeld B, Eichhorn EJ. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. The American Journal of Cardiology. 15 Feb 1995;75(5):360-364.
24. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol. 15 Jun 1995;75(17):1220-1223.
25. BEST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 31 May 2001;344(22):1659-1667.
26. Torp-Pedersen C, Kober L, Ball S, Hall A, Brendorp B, Ottesen M, et al. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology. Aug 2002;4(4):495-499.
27. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. The American Journal of Cardiology. 1 Mar 2005;95(5):558-564.
28. Wehling M. Comparison beta-blockers and their relevance to pharma-cologic therapy of cardiovascular diseases. Arzneimittel-Forschung. 2002;52(2):73-80.
29. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. Jun 2007;27(6):874-887.
30. Hong-Guanga X, Dishy V, Sofowora G, Kim RB, Landau RB, Smiley RM, et al. Arg389Gly [beta]1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics. April 2001;11(2):191-197.
31. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 23 Aug 2002;277(34):30429-30425.
32. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1- adrenergic receptor. J Biol Chem. 30 Apr 1999;274(18):12670-12674.
33. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. Oct 2003; 9(10):1300-1305.
34. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics. Mar 2005;15(3):143-149.
35. Magnusson Y, Levin MC, Eggertsen R, Nystrom E, Mobini R, Schaufelberger M, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. Sep 2005;78(3):221-231.
36. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 25 Jul 2006;103(30):11288-11293.
37. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. Journal of Cardiac Failure. Oct 2003;9(5):354-363.
38. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, et al. An evaluation of the beta-1 adrenergic receptor Arg389-Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. Aug 2003;5(4):463-8.
39. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 19 Aug 2008;52(8):644-651.
40. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol. 4 Dec 1997;80(11A):7L-14L.
41. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2- adrenergic receptors regulate sympathetic neurotransmission. Nature. 11 Nov 1999; 402(6758):181-184.
42. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circulation Heart failure. Jan 2010;3(1):21-28.
43. Liggett SB M-PJ, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D. et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288-11293.
44. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 28 Jul 2000;275(30):23059-23064.
45. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation. 5 Nov 2002;106(19):2491-2496.
46. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 10 Oct 2002;347(15):1135-1142.
47. Gerson MC, Wagoner LE, McGuire N, Liggett SB. Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor. J Nucl Cardiol. Nov-Dec 2003;10(6):583-589.
48. Kaye DM, Smirk B, Finch S, Williams C, Esler MD. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adren-ergic receptor genotype. J Am Coll Cardiol. 16 Nov 2004;44(10):2008-2015.
49. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002(4):CD002992.
50. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. Jun 2004; 125(6):2309-2301.
51. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535-540.
52. Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25(2):131-144.
53. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, et al. Gender differences in advanced heart failure: insights from the BEST study. Journal of the American College of Cardiology. 17 Dec 2003;42(12):2128-2134.
54. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology. 1 Oct 2003;42(7):1238-1245.
55. Hoffstedt J, Lonnqvist F, Shimizu M, Blaak E, Arner P. Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity. May 1996; 20(5):428-434.
56. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology. 3 Sep 2003;42(5):914-922.
57. Reinhart K, White, CM. Bucindolol: a beta-blocker for the treatment of heart failure. 2009 [updated 2009; cited 2011 Febraury 23]; http://chromatogra-phyonline.fndanalytichem.com/lcgc/article/articleDetail.jsp?id=601855. Available from.
58. Fardoun RZ. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus. Pharmacotherapy. Oct 2006;26(10):1491-1500.
59. Balamuthusamy S, Molnar J, Adigopula S, Arora R. Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. Am J Ther. Mar-Apr 2009;16(2):133-142.
60. Haas SJ, Vo s T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? a meta-analysis of large-scale clinical trials. Am Heart J. Nov 2003;146(5):848-853.
61. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 5 May 2001;357(9266):1385-1390.
62. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc. Aug 2009;84(8):718-729.
63. Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker beneft according to severity of heart failure. European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology. Jun 2003;5(3):281-289.
64. Eichhorn EJ, Grayburn PA, Mayer SA, St John Sutton M, Appleton C, Plehn J, et al. Myocardial contractile reserve by dobutamine stress echocar-diography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation. 11 Nov 2003;108(19):2336-2341.
65. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 12 Jun 1999;353(9169):2001-2007.
66. A randomized trial of beta-blockade in heart failure. The Cardiac Insuf-fciency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. Oct 1994;90(4):1765-1773.
67. Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. The American Journal of Cardiology. 15 Oct 2000;86(8):886-889.
68. Coats AJ. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs and Aging. 2006;23(2):93-99.
69. Bhatia RS, Tu J V, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 20 Jul 2006;355(3):260-269.
70. Holland D, Kumbhani DJ, Ahmed SH, and Marwick, TH. Effects of Treatment on Exercise Tolerance, Cardiac Function and Mortality in Heart Failure with Preserved Ejection Fraction; A Meta-Analysis. J Am Coll Cardiol. 2011;57:1676-1686.
71. Eichhorn EJ. Effects of bucindolol in heart failure. The American Journal of Cardiology. 25 Mar 1993;71(9):65C-70C.
72. Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. Mar-Apr 2010;62(2):101-110.
73. Frantz RP, Lowes BD, Grayburn PA, White M, Krause-Steinrauf H, Krishnan V, et al. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral sub study of the Beta-Blocker Evaluation of Survival Study (BEST). Journal of Cardiac Failure. Aug 2007;13(6):437-434.
74. Heartwire. FDA rejects application of beta blocker intended for genotype-guided heart-failure therapy http://www.theheart.org/article/975907.do; 2011 [updated 2011 June 2, 2009; cited 2011 24 Feb]; Available from.
75. News-medical. ARCA receives European Patent for bucindolol based treatment for heart failure. http://www.news-medical.net/news/20101008/ARCA-receives-European-Patent-for-bucindolol-based-treatment-for-heart-failure.aspx; 2010 [updated 2010 8 October 2010; cited 2011 24 Feb]; Available from.
76. Mancini D, LeJemtel T, Aaronson K. Peak VO(2): a simple yet enduring standard. Circulation. 14 Mar 2000;101(10):1080-1082.
77. Tate CW, 3rd, Robertson AD, Zolty R, Shakar SF, Lindenfeld J, Wolfel EE, et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). Journal of Cardiac Failure. Nov 2007;13(9):732-773.
78. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 31 May 2001;344(22):1651-1658.
79. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. Feb 2005;26(3):215-215.
80. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 14 Sep 2004;110(11):1437-1442.